Major Research Findings

Tapinarof is a novel aryl hydrocarbon receptor modulator approved for adult psoriasis. 1 It has shown good efficacy in long-term treatment, with a favorable safety profile, and appears to have a promising remitting effect. 1 It is currently being studied for pediatric psoriasis. 2

Roflumilast, a phosphodiesterase type 4 inhibitor, is approved for the treatment of plaque psoriasis in patients aged 12 years and older. 2 It has been shown to be effective in improving lesions and managing pruritus. 1 While studies show promising results for intertriginous areas, larger trials are needed. 1

Reasons for Side Effects

New topical medications like tapinarof and roflumilast have different mechanisms of action compared to traditional treatments like corticosteroids and vitamin D analogs. This difference in how they work can lead to different side effects. 1

Common Side Effects

Tapinarof

Side effects of tapinarof are generally mild and often improve with continued use. 1 Reported side effects include rash, itching, dry skin, and flushing. 1

Side Effects Management

Tapinarof

If you experience any concerning side effects from tapinarof, consult your doctor. 1

Research Comparison

Similarities

Research on both tapinarof and roflumilast demonstrates that these medications have fewer side effects compared to traditional treatments, while offering promising efficacy. 1 2

Differences

Tapinarof is approved for adult psoriasis. 1 Roflumilast is approved for plaque psoriasis in patients aged 12 years and older. 2 Tapinarof has shown a promising remitting effect with an average relapsing time of over 3 months. 1

Real-Life Application Considerations

Tapinarof and roflumilast are effective new topical medications for psoriasis. 1 2 However, as with any medication, side effects are possible. Consult your doctor for proper treatment and management. 1 2

Current Research Limitations

Research on tapinarof and roflumilast is still in its early stages. 1 2 Further studies are needed to assess long-term safety and efficacy. 1 2

Future Research Directions

Research is needed to evaluate long-term safety and efficacy of tapinarof and roflumilast. 1 2 Studies investigating the combined effects of these medications with other treatment options are also warranted. 1 2

Conclusion

Tapinarof and roflumilast are promising new topical medications for psoriasis with fewer side effects compared to traditional treatments. 1 2 However, side effects can occur, so consult your doctor for appropriate treatment and management. 1 2 If you have psoriasis, talk to your doctor to find the best treatment plan for you. 1 2